[Involvement of tau protein kinase in amyloid-beta-induced neurodegeneration]
- PMID: 9816911
[Involvement of tau protein kinase in amyloid-beta-induced neurodegeneration]
Abstract
Histopathological features of Alzheimer's disease (AD) include extracellular deposits of amyloid beta (A beta) fibrils in the cores of senile plaques, intracellular neurofibrillary tangles (NFT) which are composed of paired helical filaments (PHF), and neuronal cell loss. The main component of PHF is highly phosphorylated tau protein. We identified a protein kinase converting normal tau into a PHF-like state. The kinase is tau protein kinase (TPK) I/glycogen synthase kinase (GSK)-3 beta. Using a neuronal cell culture system as an AD model, it was recognized that TPK I/GSK-3 beta plays a central role in AD pathology. We hypothesize that A beta-induced neuronal cell death occurs by the following mechanism. A beta inactivates PI3-kinase and activates TPK I/GSK-3 beta, which in turn phosphorylates and inactivates both tau and pyruvate dehydrogenase (PDH). After the ability of tau to promote microtubule assembly is diminished by phosphorylation, soluble tau molecules aggregate into PHF by an unknown mechanism. Destabilization of microtubule arrays causes inhibition of axonal transport and accumulation of amyloid precursor protein (APP). Phosphorylation of PDH inhibits the reaction converting pyruvate to acetyl-CoA, resulting in inhibition of energy metabolism and a decrease in acetylcholine, both of which are also characteristics of AD. These changes may lead to neuronal cell death.
Similar articles
-
Physiology and pathology of tau protein kinases in relation to Alzheimer's disease.J Biochem. 1997 Feb;121(2):179-88. J Biochem. 1997. PMID: 9089387 Review.
-
Glycogen synthase kinase-3 is associated with neuronal and glial hyperphosphorylated tau deposits in Alzheimer's disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration.Acta Neuropathol. 2002 Dec;104(6):583-91. doi: 10.1007/s00401-002-0587-8. Epub 2002 Jul 13. Acta Neuropathol. 2002. PMID: 12410379
-
The active form of glycogen synthase kinase-3beta is associated with granulovacuolar degeneration in neurons in Alzheimer's disease.Acta Neuropathol. 2002 Feb;103(2):91-9. doi: 10.1007/s004010100435. Epub 2001 Nov 29. Acta Neuropathol. 2002. PMID: 11810173
-
Role of glycogen synthase kinase-3 in Alzheimer's disease pathogenesis and glycogen synthase kinase-3 inhibitors.Expert Rev Neurother. 2010 May;10(5):703-10. doi: 10.1586/ern.10.40. Expert Rev Neurother. 2010. PMID: 20420491
-
GSK-3 inhibitors for Alzheimer's disease.Expert Rev Neurother. 2007 Nov;7(11):1527-33. doi: 10.1586/14737175.7.11.1527. Expert Rev Neurother. 2007. PMID: 17997701 Review.
Cited by
-
GSK3 inhibitors show benefits in an Alzheimer's disease (AD) model of neurodegeneration but adverse effects in control animals.Neurobiol Dis. 2009 Feb;33(2):193-206. doi: 10.1016/j.nbd.2008.10.007. Epub 2008 Nov 5. Neurobiol Dis. 2009. PMID: 19038340 Free PMC article.
-
Effect of GSK-3 overactivation on neurofilament phosphorylation.J Huazhong Univ Sci Technolog Med Sci. 2005;25(4):375-7, 403. doi: 10.1007/BF02828200. J Huazhong Univ Sci Technolog Med Sci. 2005. PMID: 16196280
-
Glycogen synthase kinase 3β (GSK3β) and presenilin (PS) are key regulators of kinesin-1-mediated cargo motility within axons.Front Cell Dev Biol. 2023 Jun 9;11:1202307. doi: 10.3389/fcell.2023.1202307. eCollection 2023. Front Cell Dev Biol. 2023. PMID: 37363727 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical